Perjeta 420 MG/14 ML vial 14ML
Ended Awarded
- Contract number
- SPE2DR26FQWC0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,302
Award facts
- Contract value 100% obligated
- $9,301.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $9,301.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. This firm fixed-price delivery order, issued on November 17, 2025, with an ultimate completion date of December 9, 2025, was awarded without set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was selected as the awardee under its role as a critical pharmaceutical supplier supporting Department of Defense healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499.99 billion with an ultimate completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. DMS Pharmaceutical Group's established performance across oncology treatments, immunosuppressants, specialty pharmaceuticals, and routine medications positions it as a key regional prime vendor contractor supporting recurring medical supply needs across the global military medical system.
Quick answers
Who was awarded contract SPE2DR26FQWC0?
SPE2DR26FQWC0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 17, 2025.
How much is contract SPE2DR26FQWC0 worth?
The government has obligated $9,302 on SPE2DR26FQWC0.
Is contract SPE2DR26FQWC0 an order under another contract?
Yes. SPE2DR26FQWC0 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWC0 competed?
The extent of competition for SPE2DR26FQWC0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award